Next, we verified that skeletal muscle-derived FSTL1-mediated NASH progression with regards to hepatic lipid metabolism, fibrosis, and inflammation in vivo when specific IRF4 deletion was induced in skeletal muscles. This evidence concerns the gene FSTL1 and metabolic dysfunction-associated steatohepatitis.